Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
It's at the Advaxis website just like some others
Today is the last day of the concention, so I suggest we hear something
8k filed about presentation
The video's are available on their website as mentionned earlier
Anavex Life Sciences will be attending the Bio International Convention from June 19th to 22nd in San Diego, California at the San Diego Convention Center.
Anyone know when?
Presenting today just at the bell
New on the website
Hear from cancer survivors in their own words
Corporate presentation has been updated I think
21 june
Aethlon Medical To Present Clinical Study Results at The BIO International Convention
Interesting programm monday
At the event, presentations will focus on Patients, Partnerships and Progress, providing updates on the company’s Lm Technology™ and nine development programs. Clinical investigators sharing their experiences and case studies during this year’s event include:
Sharad Ghamande, MD, an associate professor and Director of Gynecologic Oncology at the Georgia Cancer Center at Augusta University, who is a principal investigator in Advaxis’ Phase 1 study of axalimogene filolisbac evaluated at higher doses in women with metastatic cervical cancer.
Cathy Eng, MD, FACP, who is a professor and the Associate Medical Director, Colorectal Center, Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center. Dr. Eng is the principal investigator in Advaxis’ Phase 2 FAWCETT study, evaluating axalimogene filolisbac in patients with metastatic anal cancer.
Nicola Mason, PhD, BVetMed, an associate professor of medicine and pathobiology at the University of Pennsylvania School of Veterinary Medicine, specializing in canine cancer, is an investigator evaluating ADXS-HER2 in dogs with surgically treated osteosarcoma.
Brian Slomovitz, MD, who is the Director of the Division of Gynecologic Oncology in the Department of Obstetrics and Gynecology at the University of Miami Miller School of Medicine, as well as Co-leader of the Gynecologic Cancers Site Disease Group at Sylvester Comprehensive Cancer Center. Dr. Slomovitz is a co-principal investigator on the company’s Phase 3 AIM2CERV trial in high-risk, locally advanced cervical cancer and an investigator evaluating axalimogene filolisbac in combination with AstraZeneca’s durvalumab in metastatic cervical cancer.
Mark Stein, MD, a medical oncologist at the Rutgers Cancer Institute of New Jersey, working across multiple disciplines in the Prostate Cancer Program and the Urologic Oncology Program, is an investigator in a Phase 1/2 trial evaluating ADXS-PSA in patients with previously treated, metastatic castration-resistant prostate cancer (mCRPC).
Advaxis senior management will also share details on the company’s clinical development, the collaboration with Amgen, Inc. on ADXS-NEO and plans for regulatory submission and commercialization. Advaxis presentations include:
Robert Petit, PhD, discussing axalimogene filolisbac and a potential prognostic biomarker, and preclinical work with Lm-WT1, ADXS-NEO and ADXS-HOT
Mayo Pujols, discussing details of the IND for ADXS-NEO
Fatima Ahmad, PharmD, sharing a publication and congress overview
Bob Ashworth, PhD, providing a EU regulatory approval update
Chris Duke presenting Advaxis’ plan for EU commercial readiness
And then realise again the pps should be much higher
Just read it, I suppose everybody will
May we get some news before ?
Anavex President & CEO Christopher U. Missling, PhD, to present preclinical data on ANAVEX 2-73™ at the Epilepsy Foundation’s Antiepileptic Drug Trials XIV Conference on May 19.
Today
3:10 ANAVEX 2-73, A Clinical Candidate for Neurodevelopmental Disorders
New article at the website
Inside Perspectives on Immunotherapy: An Interview with Advaxis CEO Daniel O’Connor
News just out
Erin Andrews to Participate in Cervical Cancer Educational Forum Hosted by Sylvester Comprehensive Cancer Center and Gilda’s Club, Sponsored by Advaxis
Time Magazine Reports Almost Half of U.S. Adults Have HPV
Patient Chris Burian Discusses Participating in Advaxis’ Clinical Trial for Head and Neck Cancer
Advaxis featured in Loncar Fund’s ‘Get to Know the Company.’
Some new highlights on the website
It's on their website
Anavex President & CEO Christopher U. Missling, PhD, to participate in a roundtable discussion at Terrapinn’s Orphan Drug Congress USA, on April 21.
Anavex President & CEO Christopher U. Missling, PhD, to participate in a roundtable discussion at Terrapinn’s Orphan Drug Congress USA, Friday, at 12:20 PM on April 21.
Wardmar Park Marriott
Washington, DC
Roundtable 4: Partnerships- successful collaboration between a rare disease foundation and a pharmaceutical company to advance preclinical and clinical research in Rett Syndrome.
1:00-1:30 pm 11 april Boston cancer advance
Maximizing Research Collaborations and Tech Transfer
Anne Deconinck, Executive Director, MIT Koch Institute; Philip Gotwals, Executive Director, Oncology Research, Novartis; Daniel O'Connor, President & CEO, Advaxis; Gary Sclar, VP, Innovations, Dana Farber Cancer Institute; Robert Spiegel, CMO, PTC Therapeutics
Moderator: Joern-Peter Halle, SVP, Head, External Innovation, EMD Serono
At 2:58 as mentionned on the programm
At 2.58 exactly
Late breaking abstract and bad news ?
During the reception, event speakers will provide an overview of Advaxis’ cervical cancer clinical program, including an update on the Phase 3 AIM2CERV study in locally advanced cervical cancer. Advaxis is currently conducting the only industry-sponsored phase 3 clinical trial in cervical cancer, and the company’s oral, late-breaker presentation on axalimogene filolisbac on March 14 is the only data on pharmacotherapeutic interventions being presented for cervical cancer during SGO’s Annual Meeting.
At 2:54
A prospective phase 2 trial of the listeria-based HPV immunotherpay axalimogene filolisbac (AXAL) in second and third-line metastatic cervical cancer: A nrg oncology group trial
W. Huh1, W.E. Brady2, D.S. Dizon3, M.A. Powell4, L.M. Landrum5, C.A. Leath III6, E.J. Tanner III7, R.V. Higgins8, S.M. Ueda9, M.T. McHale10 and C. Aghajanian11
1University of Alabama at Birmingham, Division of Gynecologic Oncology, Birmingham, AL, USA, 2Gynecologic Oncology Group Statistical and Data Center, Buffalo, NY, USA, 3Massachusetts General Hospital Cancer Center, Boston, MA, USA, 4Washington University School of Medicine in St. Louis, St. Louis, MO, USA, 5The University of Oklahoma, Oklahoma City, OK, USA, 6University of Alabama at Birmingham, Birmingham, AL, USA, 7Johns Hopkins Hospital, Baltimore, MD, USA, 8Levine Cancer Institute, Carolinas Medical Center, Charlotte, NC, USA, 9UCSF Helen Diller Comprehensive Cancer Center, San Francisco, CA, USA, 10UCSD Rebecca and John Moores Cancer Center, La Jolla, CA, USA, 11Weill Cornell Medical College, New York, NY, USA
W. Huh1, W.E. Brady2, D.S. Dizon3, M.A. Powell4, L.M. Landrum5, C.A. Leath III6, E.J. Tanner III7, R.V. Higgins8, S.M. Ueda9, M.T. McHale10 and C. Aghajanian11
1University of Alabama at Birmingham, Division of Gynecologic Oncology, Birmingham, AL, USA, 2Gynecologic Oncology Group Statistical and Data Center, Buffalo, NY, USA, 3Massachusetts General Hospital Cancer Center, Boston, MA, USA, 4Washington University School of Medicine in St. Louis, St. Louis, MO, USA, 5The University of Oklahoma, Oklahoma City, OK, USA, 6University of Alabama at Birmingham, Birmingham, AL, USA, 7Johns Hopkins Hospital, Baltimore, MD, USA, 8Levine Cancer Institute, Carolinas Medical Center, Charlotte, NC, USA, 9UCSF Helen Diller Comprehensive Cancer Center, San Francisco, CA, USA, 10UCSD Rebecca and John Moores Cancer Center, La Jolla, CA, USA, 11Weill Cornell Medical College, New York, NY, USA
Let's see what SGO will bring
Late-breaking Abstracts
Scientific Plenary VI: Late Breaking Abstracts
Tuesday, March 14
2:30 p.m. – 3:30 p.m.
Reception on monday
And manipulation will stop
Taking all the stoplosses out, don' t set them if you believe in the science.
BioNJ Announces Newly Elected Board Chair, Officers and Trustees
TRENTON, N.J. - (February 14, 2016) - BioNJ, The Gateway to Health, announced the election of its 2017 Officers and Board Members. The Board appointments preceded BioNJ's 24th Gateway Gala and Innovation Celebration on February 2 at the Hilton East Brunswick where 650 industry leaders turned out to celebrate the industry and its many accomplishments over dinner, networking and awards presentations.
Newly elected Officers are Chairman James Sapirstein, R.Ph., M.B.A., Chief Executive Officer, ContraVir Pharmaceuticals, Inc.; Vice Chair Daniel J. O'Connor, President, Chief Executive Officer and Director, Advaxis, Inc.; Treasurer Scott White, President, Oncology, Janssen Biotech, Inc., a Johnson & Johnson Company and Secretary Christian Kopfli, Esq., Chief Executive Officer, Chromocell Corporation.
"Because Patients Can't Wait®, we are grateful for our talented and dedicated Board whose guidance is invaluable to enabling our Mission," said BioNJ President and CEO Debbie Hart.
James Sapirstein, R.Ph., M.B.A., Chief Executive Officer, ContraVir Pharmaceuticals, Inc. was elected Chairman of BioNJ, succeeding Stuart Peltz, Ph.D., Chief Executive Officer, PTC Therapeutics who concluded a two-year term and moves into the Immediate Past Chairman's role.
"It is an honor to serve as the Chair of BioNJ, and to follow the strong leaders before me. BioNJ is a vital organization to our ecosystem and will play an increasingly important role as we face new challenges on so many fronts in the coming months. I look forward to working with the Board and the team to help advance the work of this industry in support of Patients," Sapirstein said.
In thanking Dr. Peltz, Hart noted that "during his tenure, Dr. Peltz was a confidant, leader and mentor whose inquisitive nature drove BioNJ to higher ground. I sincerely thank Dr. Peltz for all that he has done during his dynamic two years as Chairman.
"I am honored that Mr. Sapirstein has agreed to join us as our Chairman. Mr. Sapirstein's notable industry experience, great passion and public policy acumen will be invaluable to BioNJ's efforts as we take on the responsibility of helping to ensure medical innovation and access for all."
James Sapirstein Elected New Chairman
Mr. Sapirstein is currently the CEO of Contravir Pharmaceuticals. After beginning his career in 1984 with Eli Lilly, he accepted a position at Hoffmann-LaRoche in 1987, where he served for almost a decade as part of its sales and marketing teams. Mr. Sapirstein then moved into the biotech arena at Gilead Sciences, Inc. He served in the Global Marketing Group at Gilead, beginning in 2000 where he led and developed the global marketing strategy for its flagship HIV drug, Viread. In 2002, he accepted the position of Executive Vice President for Serono Laboratories where he led a team of over 100 professionals to rebuild a struggling HIV and pediatric growth hormone business. As the founding CEO of Tobira Therapeutics, a New Jersey-based biopharmaceutical company focused on the development of novel HIV and infectious disease compounds, Mr. Sapirstein was instrumental in helping to raise over $60 million in venture capital and research funding to enable Tobira to further its scientific development. Just prior to joining Contravir, Mr. Sapirstein was CEO of Alliqua Therapeutics at Alliqua, Inc.
BioNJ Board Officers Include :
Newly elected Vice Chairman: Daniel J. O'Connor, President, Chief Executive Officer and Director, Advaxis, Inc. Mr. O'Connor was appointed Advaxis' President and Chief Executive Officer in August 2013 at a time when the company was a "penny stock," had no cash and was burdened with significant debt. Undeterred, he executed a turnaround strategy rooted in an understanding of the potential of Advaxis' Lm Technology™ platform and has successfully transformed Advaxis financially, clinically and operationally, providing a strong balance sheet that has enabled the company to advance one of the most diverse and active immunotherapy pipelines in the industry.
Newly named Treasurer: Scott White, President, Oncology, Janssen Biotech, Inc., Janssen Pharmaceutical Companies of Johnson & Johnson
Mr. White began his career with Johnson & Johnson 24 years ago in R&D developing high-throughput screening assays for Drug Discovery followed by several years in Clinical Research and Development. He has enjoyed a broad and diverse career holding various discovery, clinical development, sales, marketing and managed markets positions across the Johnson & Johnson family of companies. In his current position, Mr. White is responsible for leading Janssen's Oncology business unit which is responsible for the commercialization of Janssen's oncology portfolio in the United States.
Secretary: Christian Kopfli, Esq., Chief Executive Officer, Chromocell
Dr. Kopfli co-founded Chromocell in 2002, serving initially as General Counsel before becoming Chief Executive Officer in 2005. Prior to joining Chromocell, he was an Associate at Davis Polk & Wardwell, working in its New York City, Tokyo and Frankfurt offices. At Davis Polk, Dr. Kopfli worked extensively in Mergers & Acquisitions, Capital Markets and Private Equity Transactions. He received a doctoral degree in law (magna cum laude) from the University of Zurich and earned his LL.M. from Columbia Law School in New York City.
At the meeting, three new Members joined the BioNJ Board of Trustees:
Sol J. Barer, Ph.D., Former Chairman, Celgene Corporation, Chairman of the Board, Edge Therapeutics, Inc.
Newly named Chairman of Teva Pharmaceuticals, Dr. Barer spent most of his professional career with the Celgene Corporation. He was Chairman from January 2011 until June 2011, Executive Chairman from June 2010 until January 2011 and Chairman and Chief Executive Officer from May 2006 until June 2010. Previously he was appointed President in 1993 and Chief Operating Officer in 1994 before assuming the CEO position. He also served as Senior Vice President, Science and Technology, and Vice President/General Manager, Chiral Products, from October 1990 to October 1993, and Vice President, Technology, from September 1987 to October 1990. Dr. Barer was the founder of the biotechnology group at the Celanese Research Company which was subsequently spun out to form Celgene. Dr. Barer serves as Chairman of the Board of Edge Therapeutics, InspireMD, Aevi Genomic Medicine and Centrexion and is Lead Director of ContraFect.
Meeta Chatterjee, Ph.D., Head, Business Strategy and Operations, Business Development and Licensing, Merck Research Laboratories
Dr. Chatterjee has 30 years of broad strategic and operational experience in pharmaceutical research and development, in-licensing and externalization activities. In her current role, she is responsible for overseeing business strategy and operations, including governance, oversight and control within the research laboratories and across divisions. Additionally, Dr. Chatterjee oversees Merck's Outlicensing/Externalization activities.
Matthew Roden, Ph.D., Vice President and Head of Strategic Corporate Development, Bristol-Myers Squibb Company
At Bristol-Myers Squibb (BMS), Dr. Roden is responsible for Business Development strategy and overseeing the Mergers & Acquisition team accountable for acquisitions, structured transactions and divestitures. Prior to joining BMS, he was most recently the Head of the Biotechnology Equity Research Team at UBS, and prior was a senior biotech analyst at Bank of America Merrill Lynch and J.P. Morgan.
Board of Trustees 2017
In addition to the officers and new Board members, M embers of the Board of Trustees are: Immediate Past Chair Dr. Stuart Peltz, Ph.D., Chief Executive Officer, PTC Therapeutics; Ambaw Bellete, President, Photocure, Inc.; Bradley Campbell, President and Chief Operating Officer, Amicus Therapeutics, Inc.; Paul G. Howes, Executive Chairman, ThromboGenics, Inc.; John Maki, President and Chief Executive Officer, Vicus Therapeutics; Anthony S. Marucci, M.B.A., Founder, President, Chief Executive Officer and Director, Celldex Therapeutics, Inc.; Geneviève Ménard, Pharm D., M.B.A., Sr. Vice President, Global Pharmaceutical Development and Operation, Celgene Corporation; Spiro Rombotis, President and Chief Executive Officer, Cyclacel Pharmaceuticals, Inc.; Alan Rubino, President and Chief Executive Officer, Emisphere Technologies, Inc.; Christopher J. Schaber, Ph.D., President and Chief Executive Officer, Soligenix, Inc.; Marco Taglietti, M.D., President and Chief Executive Officer, SYNEXIS, Inc. and Ji Zhang, Ph.D., Senior Vice President, Head of R&D Operations, Sanofi.
Returning Board Advisors include: Rajeev Dadoo, Ph.D., Partner, SROne; Denis Segota, Esq., Partner, Morgan, Lewis & Bockius, LLP; Kenneth Somberg, M.D., Chief Medical Officer, Covance and Anthony Torrington, C.P.A., Partner, EY, LLP.
About BioNJ
BioNJ, The Gateway to Health, is a network of 400 Members representing research-based life sciences companies and stakeholders dedicated to propelling a vibrant ecosystem where Science is Supported, Companies are Created, Drugs are Developed and Patients are Paramount. Because Patients Can't Wait®, BioNJ supports its Members in the discovery, development and commercialization of therapies and cures that save and improve lives and lessen the burden of illness and disease to society by driving capital formation, fostering entrepreneurship, advocating for public policies that advance medical innovation, providing access to talent and education and offering a cost-saving array of critical commercial resources. For more information about BioNJ, please visit www.BioNJ.org.
Great ? News
Aethlon Medical Reports Results of Cytomegalovirus, Epstein-Barr and Herpes Simplex Virus Studies
Can Anything Be Learned From Alzheimer's Drug Failures?
Nice article
Already the 4th time, they surely want the pps down
And even now again on sunday, every time the same stuff
Energous Receives Edison Award for WattUp Wireless Charging Technology
Out today
Exactly when the pps went up some days the put it out again
3 articles last 10 days with the same content
There is an article from the street, read it already two times before, why ?
SGO
3 – Late Breaking Abstract
A prospective phase II trial of the listeria-based human papillomavirus immunotherpay axalimogene filolisbac in second- and third-line metastatic cervical cancer: A NRG oncology group trial
Huha, W.E. Bradyb, D.S. Dizonc, M.A. Powelld, L.M. Landrume, C.A. Leath IIIf, E.J. Tanner IIIg, R.V. Higginsh, S.M. Uedai, M.T. McHalejand C. Aghajaniank. aUniversity of Alabama at Birmingham, Division of Gynecologic Oncology, Birmingham, AL, USA, bGynecologic Oncology Group Statistical and Data Center, Buffalo, NY, USA, cMassachusetts General Hospital/Harvard University, Boston, MA, USA, dWashington University School of Medicine in St. Louis, St. Louis, MO, USA, eThe University of Oklahoma, Oklahoma City, OK, USA, fUniversity of Alabama at Birmingham, Birmingham, AL, USA, gJohns Hopkins Hospital, Baltimore, MD, USA, hLevine Cancer Institute, Carolinas Medical Center, Charlotte, NC, USA, iUCSF Helen Diller Comprehensive Cancer Center, San Francisco, CA, USA, jUCSD Rebecca and John Moores Cancer Center, La Jolla, CA, USA, kWeill Cornell Medical College, New York, NY, USA